Skip to main content Accessibility help
×
Home

Deferiprone Reduces Hemosiderin Deposition in Superficial Siderosis

  • Pei-Hsin Kuo (a1), Sheng-Han Kuo (a2) and Raymond Y. Lo (a1)
  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Deferiprone Reduces Hemosiderin Deposition in Superficial Siderosis
      Available formats
      ×

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Deferiprone Reduces Hemosiderin Deposition in Superficial Siderosis
      Available formats
      ×

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Deferiprone Reduces Hemosiderin Deposition in Superficial Siderosis
      Available formats
      ×

Abstract

  • An abstract is not available for this content so a preview has been provided below. To view the full text please use the links above to select your preferred format.

Copyright

References

Hide All
1. Schmitz-Hubsch, T, du Montcel, ST, Baliko, L, et al. Scale for the assessment and rating of ataxia: development of a new clinical scale. Neurology. 2006;66:1717-1720.
2. Levy, M, Llinas, RH. Update on a patient with superficial siderosis on deferiprone. AJNR Am J Neuroradiol. 2012;33:E99-100.
3. Levy, M, Llinas, R. Pilot safety trial of deferiprone in 10 subjects with superficial siderosis. Stroke. 2012;43:120-124.
4. Cossu, G, Abbruzzese, G, Matta, G, et al. Efficacy and safety of deferiprone for the treatment of pantothenate kinase-associated neurodegeneration (PKAN) and neurodegeneration with brain iron accumulation (NBIA): results from a four years follow-up. Parkinsonism Relat Disord. 2014;20:651-654.
5. Pandolfo, M, Arpa, J, Delatycki, MB, et al. Deferiprone in Friedreich ataxia: a 6-month randomized controlled trial. Ann Neurol. 2014;76:509-521.

Keywords

Deferiprone Reduces Hemosiderin Deposition in Superficial Siderosis

  • Pei-Hsin Kuo (a1), Sheng-Han Kuo (a2) and Raymond Y. Lo (a1)

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed